Eli Lilly Lilly
Biotech

Lilly inks $2.8B AtaiBeckley psychedelic buyout to challenge J&J

Continuing its takeover spree, Lilly is moving into a psychedelic mental health sector targeted by companies including Johnson & Johnson.
Nick Paul Taylor Jul 16, 2026 7:32am
Jennifer Doudna arriving at the laureates Get together at the Nobel Prize Museum in Stockholm on 6 December 2022

Nobel Laureate Jennifer Doudna enters AI protein design arena

Jul 16, 2026 2:00pm
Panther Rare Pharmacy

De-risking rare disease launches: precision beats scale

Brought to you by PANTHERx® Rare Pharmacy
doctor taking umbilical cord from tube

Axiom hopes it ‘solved 2 major potholes’ for stem cell biotechs

Jul 16, 2026 10:40am
Completing steps towards success checkmark on cubes symbolizing progress

Racing Takeda, InnoCare reports TYK2 inhibitor win in vitiligo

Jul 16, 2026 9:36am
IPO initial public offering Wall Street

Vogenx joins the IPO queue to fund phase 2-stage metabolic drug

Jul 16, 2026 5:19am
More News

Braveheart files for IPO to support Hengrui-licensed cardio asset

Jul 15, 2026 1:40pm

With $315M raise, AdvanCell puts radiotherapy pedal to the metal

Jul 15, 2026 10:50am

J&J axes eye disease gene therapy after key phase 2b readout

Jul 15, 2026 10:26am

Fierce Biotech Fundraising Tracker '26: AdvanCell, Draig & more

Jul 15, 2026 9:00am